Lexaria Bioscience (LEXX) Stock Forecast & Price Target

Lexaria Bioscience Corp's innovative DehydraTECH technology is expected to significantly improve the bioavailability of numerous active pharmaceutical ingredients (APIs), which could drive higher market adoption, particularly for GLP-1 drugs, by enhancing their safety profile and reducing patient dropout rates. The estimated increase in shares outstanding to 33 million by the end of FY2026 suggests a proactive approach to managing equity as the company expands its licensing revenue from this proprietary technology. Furthermore, recent management insights highlighting the unusually robust performance of Rybelsus, which demonstrates effective body weight reduction metrics over time, reinforce the potential for increased demand for Lexaria's drug delivery solutions in the competitive pharmaceutical landscape.

Lexaria Bioscience Corp reported a significant net loss of $3.8 million for fiscal 3Q25, equating to a loss of $0.21 per share, which raises concerns about the company's financial sustainability. The company's DehydraTECH technology, while innovative, demonstrated a minimal HbA1c reduction of -0.14% in its testing with semaglutide, indicating limited efficacy in a critical therapeutic area. Additionally, the potential for gastrointestinal adverse events (AEs) associated with GLP-1 drugs raises further doubts about the long-term viability and market acceptance of the company’s offerings.